GLP1R and metabolic syndrome: Other favorable results concern other components of metabolic syndrome, namely blood pressure values, both systolic and diastolic, which decreased significantly in the 12 months of treatment with GLP-1 RAs, and also serum uric acid levels, which were significantly reduced, similarly to the results of the same SELECT randomized controlled trial and also to the results of several meta-analyses with this class of antihyperglycemic agents, although each was carried out with a completely different design not directly comparable with this real-world sample [26,27,28,29].